$CATX
Perspective Therapeutics Inc Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-K Financial Statement

#000143774920020189 Filed on September 25, 2020

Income Statement

Concept	2020 Q3	2019 Q2	2019 Q1
Revenue	$2.384M	$1.924M	$1.924M
YoY Change	2.98%	20.02%	22.31%
Cost Of Revenue	$1.138M	$1.045M	$1.045M
YoY Change	5.47%	-10.68%	8.4%
Gross Profit	$1.246M	$879.0K	$879.0K
YoY Change	0.81%	98.42%	44.33%
Gross Profit Margin	52.27%	45.69%	45.69%
Selling, General & Admin	$1.648M	$1.682M	$1.744M
YoY Change	-13.81%	-24.91%	18.24%
% of Gross Profit	132.26%	191.35%	198.41%
Research & Development	$312.0K	$341.0K	$299.0K
YoY Change	33.91%	-40.18%	-36.79%
% of Gross Profit	25.04%	38.79%	34.02%
Depreciation & Amortization	$34.00K	$49.00K	$47.00K
YoY Change	-10.53%	63.33%	56.67%
% of Gross Profit	2.73%	5.57%	5.35%
Operating Expenses	$1.960M	$2.023M	$2.042M
YoY Change	-5.41%	-27.75%	4.83%
Operating Profit	-$714.0K	-$1.144M	-$1.163M
YoY Change	-14.59%	-51.46%	-13.14%
Interest Expense	$1.000K	$49.00K	$34.00K
YoY Change	-95.0%	390.0%	240.0%
% of Operating Profit
Other Income/Expense, Net	$1.000K	$0.00	$36.00K
YoY Change	-95.0%		414.29%
Pretax Income	-$713.0K	-$1.095M	-$1.127M
YoY Change	-12.62%	-53.6%	-15.26%
Income Tax
% Of Pretax Income
Net Earnings	-$713.0K	-$1.095M	-$1.127M
YoY Change	-12.62%	-53.27%	-15.39%
Net Earnings / Revenue	-29.91%	-56.91%	-58.58%
Basic Earnings Per Share	-$0.01
Diluted Earnings Per Share	-$10.35K	-$16.26K	-$16.74K
COMMON SHARES
Basic Shares Outstanding	68.90M	67.34M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q3	2019 Q2	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.940M	$5.326M	$6.392M
YoY Change	-57.6%	55.28%	41.42%
Cash & Equivalents	$1.940M	$5.326M	$4.059M
Short-Term Investments		$0.00	$2.333M
Other Short-Term Assets	$407.0K	$27.00K	$390.0K
YoY Change	94.74%	-6.9%	2.63%
Inventory	$641.0K	$530.0K	$533.0K
Prepaid Expenses
Receivables	$1.758M	$1.154M	$1.116M
Other Receivables	$0.00	$86.00K	$0.00
Total Short-Term Assets	$4.746M	$7.315M	$8.431M
YoY Change	-30.27%	34.32%	33.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.814M	$1.609M	$1.564M
YoY Change	8.69%	22.73%	27.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$128.0K	$162.0K	$160.0K
YoY Change	-15.23%	-18.18%	-16.67%
Total Long-Term Assets	$3.279M	$2.107M	$2.148M
YoY Change	-1.18%	4.88%	7.56%
TOTAL ASSETS
Total Short-Term Assets	$4.746M	$7.315M	$8.431M
Total Long-Term Assets	$3.279M	$2.107M	$2.148M
Total Assets	$8.025M	$9.422M	$10.58M
YoY Change	-20.73%	26.38%	27.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$758.0K	$683.0K	$1.001M
YoY Change	-22.97%	-50.86%	30.0%
Accrued Expenses	$764.0K	$438.0K	$354.0K
YoY Change	12.02%	-0.45%	1.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.522M	$1.121M	$1.355M
YoY Change	-8.64%	-38.91%	20.66%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.408M	$621.0K	$613.0K
YoY Change	-6.32%	5.25%	5.69%
Total Long-Term Liabilities	$1.408M	$621.0K	$613.0K
YoY Change	-6.32%	5.25%	5.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.522M	$1.121M	$1.355M
Total Long-Term Liabilities	$1.408M	$621.0K	$613.0K
Total Liabilities	$2.930M	$1.742M	$1.968M
YoY Change	-7.54%	-28.16%	15.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$88.65M	-$84.49M	-$83.40M
YoY Change	3.92%	6.48%	8.38%
Common Stock	$93.75M	$92.17M	$92.01M
YoY Change	1.61%	9.24%	10.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.095M	$7.680M	$8.611M
YoY Change
Total Liabilities & Shareholders Equity	$8.025M	$9.422M	$10.58M
YoY Change	-20.73%	26.38%	27.12%

Cashflow Statement

Concept	2020 Q3	2019 Q2	2019 Q1
OPERATING ACTIVITIES
Net Income	-$713.0K	-$1.095M	-$1.127M
YoY Change	-12.62%	-53.27%	-15.39%
Depreciation, Depletion And Amortization	$34.00K	$49.00K	$47.00K
YoY Change	-10.53%	63.33%	56.67%
Cash From Operating Activities	-$338.0K	-$985.0K	-$1.338M
YoY Change	-48.24%	-32.07%	23.89%
INVESTING ACTIVITIES
Capital Expenditures	$113.0K	-$105.0K	-$128.0K
YoY Change	15.31%	-19.23%	60.0%
Acquisitions
YoY Change
Other Investing Activities		$2.344M	$2.333M
YoY Change		77.58%	302.24%
Cash From Investing Activities	-$113.0K	$2.239M	$2.205M
YoY Change	15.31%	86.58%	341.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		13.00K	-9.000K
YoY Change		-97.29%
NET CHANGE
Cash From Operating Activities	-$338.0K	-985.0K	-1.338M
Cash From Investing Activities	-$113.0K	2.239M	2.205M
Cash From Financing Activities		13.00K	-9.000K
Net Change In Cash	-$451.0K	1.267M	858.0K
YoY Change	-39.95%	450.87%	-247.93%
FREE CASH FLOW
Cash From Operating Activities	-$338.0K	-$985.0K	-$1.338M
Capital Expenditures	$113.0K	-$105.0K	-$128.0K
Free Cash Flow	-$451.0K	-$880.0K	-$1.210M
YoY Change	-39.95%	-33.33%	21.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0000728387
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	68897779
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019Q4	dei	Entity Public Float EntityPublicFloat	41406456
CY2020	dei	Entity Registrant Name EntityRegistrantName	IsoRay, Inc.
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2020	dei	Trading Symbol TradingSymbol	isr
CY2020Q2	isr	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	352000
CY2019Q2	isr	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	89000
CY2020Q2	isr	Accrued Payroll And Related Taxes Noncurrent AccruedPayrollAndRelatedTaxesNoncurrent	55000
CY2019Q2	isr	Accrued Payroll And Related Taxes Noncurrent AccruedPayrollAndRelatedTaxesNoncurrent
CY2018	isr	Adjustments To Additional Paid In Capital Sharebased Compensation Third Party Services AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationThirdPartyServices	203000
CY2018	isr	Adoption Of Asu201609 Reclassification From Retained Earnings To Additional Paid In Capital AdoptionOfASU201609ReclassificationFromRetainedEarningsToAdditionalPaidInCapital
CY2019Q3	isr	Aro Discount Amount Interest Rate AroDiscountAmountInterestRate	0.051
CY2019Q3	isr	Aro Original Obligation Amount AroOriginalObligationAmount	704000
CY2019Q3	isr	Asset Retirement Obligation After Adjustment AssetRetirementObligationAfterAdjustment	555000
CY2018	isr	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	0.01
CY2018	isr	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued	0.28
CY2019	isr	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued	0.76
CY2018	isr	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	250000
CY2018	isr	Class Of Warrant Or Right Issued For Services ClassOfWarrantOrRightIssuedForServices	500000
CY2019	isr	Class Of Warrant Or Right Issued For Services ClassOfWarrantOrRightIssuedForServices	5830000
CY2019	isr	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1
CY2020	isr	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1
CY2019Q3	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	73000
CY2020	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	73000
CY2019	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate
CY2018	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate
CY2020	isr	Income Tax Reconciliation Change In Estimate IncomeTaxReconciliationChangeInEstimate	-58000
CY2019	isr	Income Tax Reconciliation Change In Estimate IncomeTaxReconciliationChangeInEstimate	-178000
CY2018	isr	Income Tax Reconciliation Change In Estimate IncomeTaxReconciliationChangeInEstimate
CY2020	isr	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	318000
CY2019	isr	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	-66000
CY2018	isr	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	17000
CY2020	isr	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	-98000
CY2019	isr	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	56000
CY2018	isr	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	2000
CY2020	isr	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	62000
CY2019	isr	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	-33000
CY2018	isr	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	37000
CY2020	isr	Noncash Expense Lease NoncashExpenseLease	4000
CY2019	isr	Noncash Expense Lease NoncashExpenseLease
CY2018	isr	Noncash Expense Lease NoncashExpenseLease
CY2020	isr	Noncash Financing Activities Warrants Issued NoncashFinancingActivitiesWarrantsIssued
CY2019	isr	Noncash Financing Activities Warrants Issued NoncashFinancingActivitiesWarrantsIssued	163000
CY2018	isr	Noncash Financing Activities Warrants Issued NoncashFinancingActivitiesWarrantsIssued
CY2020Q2	isr	Operating Loss Carryforwards With No Expiration OperatingLossCarryforwardsWithNoExpiration	7700000
CY2015Q4	isr	Purchase Agreement Period PurchaseAgreementPeriod	P1Y
CY2020	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement
CY2019	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement	45000
CY2018	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement	395000
CY2020	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	1126000
CY2019	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	1429000
CY2018	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	1351000
CY2020Q2	isr	Restocking Fee Percentage RestockingFeePercentage	0.5
CY2020Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	654000
CY2019Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	683000
CY2020Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	35000
CY2019Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	133000
CY2020Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	204000
CY2019Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	142000
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7517000
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7370000
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	93592000
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	92105000
CY2020	us-gaap	Adjustment For Amortization AdjustmentForAmortization	38000
CY2019	us-gaap	Adjustment For Amortization AdjustmentForAmortization	50000
CY2018	us-gaap	Adjustment For Amortization AdjustmentForAmortization	50000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	11000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	11000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	11000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	404000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	420000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	495000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	495000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	420000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	404000
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	26000
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	26000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	50000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	50000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11636570
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10784380
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4086905
CY2019Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	621000
CY2018Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	590000
CY2020Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	577000
CY2020	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	29000
CY2019	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	31000
CY2018	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	29000
CY2020Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	577000
CY2019Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	621000
CY2020Q2	us-gaap	Assets Assets	8699000
CY2019Q2	us-gaap	Assets Assets	9422000
CY2020Q2	us-gaap	Assets Current AssetsCurrent	5507000
CY2019Q2	us-gaap	Assets Current AssetsCurrent	7315000
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2392000
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5326000
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2600000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5507000
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2781000
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6113000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2573000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2934000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2726000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3332000
CY2017Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
CY2018Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.54
CY2019Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2020Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0
CY2019Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5830000
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6080000
CY2017Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding
CY2018Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	250000
CY2019Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6080000
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68897779
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67388047
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68897779
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67388047
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	69000
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	67000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4556000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4267000
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4081000
CY2019Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16248000
CY2020Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2019Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2020Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15799000
CY2020Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16987000
CY2019Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15207000
CY2020Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6000
CY2019Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6000
CY2020Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	124000
CY2019Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	204000
CY2020Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	218000
CY2019Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	96000
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	682000
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	578000
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Asset Retirement Obligations DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAssetRetirementObligations	121000
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Asset Retirement Obligations DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAssetRetirementObligations	130000
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	37000
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	27000
CY2020Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16987000
CY2019Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16248000
CY2020	us-gaap	Depreciation Depreciation	147000
CY2019	us-gaap	Depreciation Depreciation	136000
CY2018	us-gaap	Depreciation Depreciation	80000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.28
CY2020Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	652000
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y91D
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	834000
CY2019Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	810000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	9000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	37000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	23000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	23000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	23000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	23000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	972000
CY2019Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	972000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	138000
CY2019Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	162000
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets
CY2019	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	24000
CY2018	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	24000
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4571000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4172000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4165000
CY2020	us-gaap	Gross Profit GrossProfit	5124000
CY2019	us-gaap	Gross Profit GrossProfit	3047000
CY2018	us-gaap	Gross Profit GrossProfit	1842000
CY2019Q3	us-gaap	Gross Profit GrossProfit	1236000
CY2019Q4	us-gaap	Gross Profit GrossProfit	1111000
CY2020Q1	us-gaap	Gross Profit GrossProfit	1706000
CY2020Q2	us-gaap	Gross Profit GrossProfit	1071000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1228000
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-7703000
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	9556000
CY2018Q3	us-gaap	Gross Profit GrossProfit	524000
CY2018Q4	us-gaap	Gross Profit GrossProfit	765000
CY2019Q1	us-gaap	Gross Profit GrossProfit	879000
CY2019Q2	us-gaap	Gross Profit GrossProfit	879000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2018	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	9500000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	739000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-724000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1080000
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1878000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	8000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	12000
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	21000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	24000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	18000
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	4000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-11000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-29000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-708000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	761000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	890000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-38000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	466000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	97000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-128000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-23000
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	20000
CY2019	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	37000
CY2018	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-88000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	121000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-30000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	64000
CY2020Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	23000
CY2019Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	31000
CY2020Q2	us-gaap	Inventory Net InventoryNet	645000
CY2019Q2	us-gaap	Inventory Net InventoryNet	530000
CY2020	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	141000
CY2019	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	210000
CY2018	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	329000
CY2020Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	137000
CY2019Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	155000
CY2020Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	401000
CY2019Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	333000
CY2020Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	221000
CY2019Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	166000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	30000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	108000
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	29000
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims
CY2019	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims
CY2018	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	203000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1131000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	290000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	261000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	290000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	290000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	126000
CY2019Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q2	us-gaap	Liabilities Liabilities	2976000
CY2019Q2	us-gaap	Liabilities Liabilities	1742000
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1575000
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1121000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-545000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-1188000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-1508000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-1414000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-1127000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-1095000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3457000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">1.</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Organization</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Isoray, Inc. was incorporated in Minnesota in <div style="display: inline; font-style: italic; font: inherit;">1983.</div> On <div style="display: inline; font-style: italic; font: inherit;"> July 28, 2005, </div>Isoray Medical, Inc. (Medical) became a wholly-owned subsidiary of Isoray, Inc. (formerly known as Century Park Pictures Corporation) pursuant to a merger. In <div style="display: inline; font-style: italic; font: inherit;"> December 2018, </div>upon approval of a majority of stockholders, Isoray, Inc. was redomiciled to Delaware. Medical was formed under Delaware law on <div style="display: inline; font-style: italic; font: inherit;"> June 15, 2004 </div>and on <div style="display: inline; font-style: italic; font: inherit;"> October 1, 2004 </div>acquired <div style="display: inline; font-style: italic; font: inherit;">two</div> affiliated predecessor companies which began operations in <div style="display: inline; font-style: italic; font: inherit;">1998.</div> Medical, a Delaware corporation, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. Medical is headquartered in Richland, Washington.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Isoray International LLC (International), a Washington limited liability company, was formed on <div style="display: inline; font-style: italic; font: inherit;"> November 27, 2007 </div>and is a wholly-owned subsidiary of Isoray, Inc. International has entered into various international distribution agreements.</div></div>
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	994000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7374000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	521000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-287000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	401000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1859000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3641000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5049000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5712000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3446000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-5144000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-6700000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-816000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-897000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5155000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6711000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	30000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	110000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	29000
CY2020	us-gaap	Open Tax Year OpenTaxYear	2018 2019 2020
CY2020	us-gaap	Operating Expenses OperatingExpenses	8600000
CY2019	us-gaap	Operating Expenses OperatingExpenses	8301000
CY2018	us-gaap	Operating Expenses OperatingExpenses	8571000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-3476000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-5254000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-6729000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	294000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	285000
CY2018	us-gaap	Operating Lease Expense OperatingLeaseExpense	285000
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1005000
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	236000
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	769000
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1001000
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y310D
CY2020Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	67500000
CY2020Q2	us-gaap	Other Assets Current OtherAssetsCurrent	27000
CY2019Q2	us-gaap	Other Assets Current OtherAssetsCurrent	27000
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	138000
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	162000
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	94000
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	74000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense
CY2020Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	273000
CY2019Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	154000
CY2020Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	31000
CY2019Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	86000
CY2020	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	11000
CY2019	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	11000
CY2018	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	11000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	14000
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	14000
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	273000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	444000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	337000
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments
CY2019	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	4725000
CY2018	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	4054000
CY2020	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments
CY2020Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	2044000
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	11000
CY2019	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	11000
CY2018	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	11000
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q2	us-gaap	Prepaid Advertising PrepaidAdvertising	14000
CY2019Q2	us-gaap	Prepaid Advertising PrepaidAdvertising	9000
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	426000
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	305000
CY2020Q2	us-gaap	Prepaid Insurance PrepaidInsurance	95000
CY2019Q2	us-gaap	Prepaid Insurance PrepaidInsurance	38000
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	34000
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
CY2019	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	5550000
CY2018	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	6268000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	131000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	50000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3000
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9252000
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8979000
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1735000
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1609000
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84492000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9680000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7314000
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5923000
CY2019Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	1154000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1126000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1474000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1746000
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	181000
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181000
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181000
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181000
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-87938000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1228000
CY2019Q3	us-gaap	Revenues Revenues	2315000
CY2019Q4	us-gaap	Revenues Revenues	2206000
CY2020Q1	us-gaap	Revenues Revenues	2880000
CY2020Q2	us-gaap	Revenues Revenues	2279000
CY2018Q3	us-gaap	Revenues Revenues	1562000
CY2018Q4	us-gaap	Revenues Revenues	1904000
CY2019Q1	us-gaap	Revenues Revenues	1924000
CY2019Q2	us-gaap	Revenues Revenues	1924000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2976000
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2679000
CY2018	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2660000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	495000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	420000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	404000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3702296
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.66
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	83000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	100000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	242000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	192810
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	561541
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	68125
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	22500
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1125000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1252500
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1330000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.39
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.31
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.34
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	151000
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	49000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	233000
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3379191
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3759840
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4645315
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5497505
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.78
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.69
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.64
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.62
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	233000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5497505
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.62
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1330000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1252500
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1125000
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.61
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.26
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.49
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.75
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.41
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.33
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.77
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.54
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.42
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.47
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.44
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.61
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	138000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y43D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y313D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y273D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y346D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y310D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y310D
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	82810
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	56900
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	262500
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	479000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7370000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	874000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	131000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	5723000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	7680000
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	10602000
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	5030000
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company's fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company's production facilities; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility, estimated lives and forfeiture rates of options granted. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.</div></div></div></div></div></div></div></div></div>
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67601000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67042000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55159000
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67388000
CY2019Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67388000
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67558000
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68075000
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	66147000
CY2018Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67331000
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67333000
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67357000

Files In Submission

Name	View Source	Status
0001437749-20-020189-index-headers.html	Edgar Link	pending
0001437749-20-020189-index.html	Edgar Link	pending
0001437749-20-020189.txt	Edgar Link	pending
0001437749-20-020189-xbrl.zip	Edgar Link	pending
chart1.jpg	Edgar Link	pending
ex_187752.htm	Edgar Link	pending
ex_187754.htm	Edgar Link	pending
ex_187755.htm	Edgar Link	pending
ex_187756.htm	Edgar Link	pending
ex_187757.htm	Edgar Link	pending
ex_187758.htm	Edgar Link	pending
ex_187759.htm	Edgar Link	pending
ex_204437.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
isr-20200630.xml	Edgar Link	completed
isr-20200630.xsd	Edgar Link	pending
isr-20200630_cal.xml	Edgar Link	unprocessable
isr-20200630_def.xml	Edgar Link	unprocessable
isr-20200630_lab.xml	Edgar Link	unprocessable
isr-20200630_pre.xml	Edgar Link	unprocessable
isr20200630_10k.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics Inc Stock $catx

2020 Q3 Form 10-K Financial Statement

#000143774920020189 Filed on September 25, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics Inc Stock $catx

2020 Q3 Form 10-K Financial Statement

#000143774920020189 Filed on September 25, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics Inc Stock $catx